INTEGRITTY

INTernational Evidence Grading Research Initiative Targeting Transparency and data qualitY (INTEGRITTY)

[Coronary 4Front @Coronary4front]

The importance of a placebo arm in interventional trials can not be overstated @GreggWStone @DLBHATTMD @mmamas1973 @drjohnm @mirvatalasnag @SABOURETCardio @gbiondizoccai @pash22 @DocSavageTJU @DFCapodanno @sbrugaletta @DavidLBrownMD @webmd11 @ovidiogarciav @VictorDayan1 @pomyers

[INTEGRITTY @INTEGRITTYgroup]

The importance of reading the supplement…

Thank you @M_Pompeu_Sa_MD for uncovering this intransparent disinformation.

How did this article pass trough the exhaustive review process of a prestigious journal like #EHJ??😦
@ehj_ed

[Michel Pompeu Sá @M_Pompeu_Sa_MD]

💥Very interesting study about #TEER vs #MitralValve surgery for severe MR just published in #EHJ… I would like to invite future readers to take a look at the supplemental files too…

@TSRA_official @EACTS @AATSJournals @ECTSS_CTsurg @STS_CTsurgery @LATAM_LACES

[Victor Dayan @VictorDayan1]

Why is it useless? Pts were randomized to invasive or conservative. Patients in the invasive arm were SELECTED (selection bias) to either CABG or PCI. Pts with more complex coronary disease went to CABG.

[Victor Dayan @VictorDayan1]

Finally…express acceptance pathway in a controversial paper ??? Come on @JACCJournals please tell me you are not in deseperate need.

[Victor Dayan @VictorDayan1]

Outcomes According to Coronary Revascularization Modality in the ISCHEMIA @JACCJournals. No information can be extracted from non randomized treatment arms. Authors and editors should know that. Thought we were over with the Stone’s def of Proc MI. https://t.co/9KMqLH4sDV

[Michel Pompeu Sá @M_Pompeu_Sa_MD]

🔥Hot off the press🔥 Read our simultaneous publication in @JAHA_AHA #AHA2023 #ScientificSessions: #SAVR vs #TAVR in low-risk patients.

🔗 https://t.co/6baczNw2a9

💪@XanderJacquemyn @JefVandenEynde @DSGMD #DannyChu @ClavelLabo @PPibarot @IbrahimSultanMD

#StructuralHeart🫀

[Mateo Marín-Cuartas @MMarinCuartas]

Meta-analysis by @M_Pompeu_Sa_MD et al, at @JAHA_AHA

💡Compared with TAVR, SAVR was associated with improved survival beyond 2 years in low-risk patients.

➡️ RCTs seem to have a protective effect that favors TAVR.

[Ash Paul @pash22]

Medicine is plagued by untrustworthy clinical trials: How many studies are faked or flawed?
In some fields, at least one-quarter of clin trials might be problematic or even entirely made up, warn some researchers. They urge stronger scrutiny.
https://t.co/OOTa7v09L6 via @Richvn

[Coronary 4Front @Coronary4front]

Eroding trust and a call to action.
How could this happen in medicine?
@INTEGRITTYgroup

[INTEGRITTY @INTEGRITTYgroup]

The ISCHEMIA trial revisited: Setting the record straight on the benefits of coronary bypass surgery and the misinterpretation of a landmark trial https://t.co/uXA2lobFnh

[Mateo Marín-Cuartas @MMarinCuartas]

The ISCHEMIA trial revisited: Setting the record straight on the benefits of coronary bypass surgery and the misinterpretation of a landmark trial
@EACTS_Journals
https://t.co/MUX8Rweuj3

[RUI M S ALMEIDA @RMSSAA]

@dr_benoy_n_shah @INTEGRITTYgroup @VictorDayan1 @drjohnm Missed you and even quoted one of your papers.

[RUI M S ALMEIDA @RMSSAA]

Honored to have been a speaker at the @EACTS meeting at the @INTEGRITTYgroup session. @drjohnm @aparolari @Migas2001 @fabiobarili @VictorDayan1 @pomyers

[Benoy Shah MD @dr_benoy_n_shah]

#EACTS2023
Next I was spoiled for choice!

Really wanted to attend @INTEGRITTYgroup, in part to hear the talks but also to meet IRL @VictorDayan1, @drjohnm & @RMSSAA whom I've only interacted with on Twitter!

However, the mitral session looked fascinating so I stayed - sorry!

[RUI M S ALMEIDA @RMSSAA]

And next week at the @EACTS meeting with my friends from @INTEGRITTYgroup, @aparolari , @AmedeoAnselmi, @drjohnm , @Migas2001, @VictorDayan1, @MMarinCuartas, @rafasadaba, @pomyers

[RUI M S ALMEIDA @RMSSAA]

The position of the @INTEGRITTYgroup about the paper by the Low Risk Trial Investigators. The saga continues.

[Victor Dayan @VictorDayan1]

Oportunidad única para financiar fellowship en Europa o USA. Pueden aplicar residentes y cirujanos de LATAM. Fecha limite 15 de Setiembre. ⁦@STS_CTsurgery⁩ ⁦@EACTS⁩

[Eduard Quintana @EduQuintanaCVS]

Remember that Trifecta constitutes 27% of all SAVRs in Notion trial. Along with others, like 10% Mitroflow .. so, almost 40% of prosthetic valves many of us consider unacceptable valve substitutes now.

Certainly upseting choices for a trial of such stakes.

[Coronary 4Front @Coronary4front]

Calls grow for a full review of the @ACCinTouch @American_Heart guideline process. Using “yes” surgeons to give the of impression of multidisciplinary collaboration just doesn’t work.

[RUI M S ALMEIDA @RMSSAA]

It’s so good to know that there are a great number of professionals, dedicated to giving the best care to patient, that can shout to what is wrong. “NEVER WHISPER IN THE PRESENCE OF WRONG”.